Facebook Twitter Instagram
    • Home
    • About Journal
      • Aim and Scope
      • Editorial Board
      • Indexing Info
      • Contact Us
    • Browse Issues
      • Articles in Press
      • Current Issue
      • Past Issues
    • For Authors
      • Instructions to Authors
      • Article Processing Charges
      • Submit your article
      • Downloads
    Facebook Twitter Instagram
    Pharmacognosy Communications
    • Home
    • About Journal
      • Aim and Scope
      • Editorial Board
      • Indexing Info
      • Contact Us
    • Browse Issues
      • Articles in Press
      • Current Issue
      • Past Issues
    • For Authors
      • Instructions to Authors
      • Article Processing Charges
      • Submit your article
      • Downloads
    Pharmacognosy Communications
    retyeyutreu
    Research Article

    Azadirachtolide: An anti-diabetic and hypolipidemic effects from Azadirachta indica leaves

    wadmin1By wadmin1July 1, 2011Updated:August 5, 2021No Comments2 Mins Read
    Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email
    Share
    Facebook Twitter LinkedIn WhatsApp Pinterest Email

    Dinesh kumar B1, Analava Mitra2, Manjunatha M2

    1Department of Pharmaceutics, PSG College of Pharmacy, Coimbatore-641 004, India.

    2School of Medical Science and Technology, Indian Institute of Technology, Kharagpur -721302, West Bengal, India

    Pharmacognosy Communications,2011,1,1,78-83
    DOI:10.5530/pc.2011.1.5
    Published: July 2011
    Type: Research Article

    ABSTRACT

    Introduction: Azadirachta indica (Meliaceae) leaves are used traditionally in the Indian Ayurvedic medicinal system to treat diabetes. The aim of the present study is to investigate the effect of azadirachtolide (tetranortriterpenoid from Azadirachta indica leaves) on blood glucose and serum lipid profiles on streptozotocin-induced diabetic rats. Methods: Streptozotocin-induced diabetic rats were used for the study. Azadirachtolide (at a dose 50 and 100 mg/kg) was administrated intra-peritoneally in diabetic rats once a week for 30 days. Biochemical parameters notably fasting blood sugar, total cholesterol, triglycerides, low-density lipoprotein, very low-density lipoprotein and high-density lipoprotein were determined. The in vitro alpha amylase and alpha glucosidase inhibitory effects of azadirachtolide were measured and IC50 values were determined. Results: Azadirachtolide exhibited significant (P < 0.05) anti-diabetic as well as hypolipidemic effects by lowering FBS, TC, TG, LDL, and VLDL levels; but also with elevation of HDL level in diabetic rats. Azadirachtolide showed appreciable alpha amylase (IC50 value of 55.80 ± 1.7 μg/ml) and alpha glucosidase inhibitory effects (IC50 value of 47.85 ± 1.4 μg/ ml) compared with acarbose (IC50 value of 83.33 ± 1.8 μg/ml). Conclusion: The present study indicated that azadirachtolide possesses anti-hyperglycemic and anti-lipidemic effects. Thus, results suggested azadirachtolide has a beneficial effect in the management of diabetes associated with abnormal lipid profile and related cardiovascular complications.

    Key words: Azadirachta indica, Azadirachtolide, Anti-diabetic, Hypolipidemic.

    Download PDF

    Share. Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email
    About Journal
    About Journal

    Pharmacognosy Communications [Phcog Commn.] is a quarterly journal published by Phcog.Net. It is a peer reviewed journal aiming to publish high quality original research articles, methods, techniques and evaluation reports, critical reviews, short communications, commentaries and editorials of all aspects of medicinal plant research. The journal is aimed at a broad readership, publishing articles on all aspects of pharmacognosy, and related fields. The journal aims to increase understanding of pharmacognosy as well as to direct and foster further research through the dissemination of scientific information by the publication of manuscripts. The submission of original contributions in all areas of pharmacognosy are welcome.
    Indexed and Abstracted in : Chemical Abstracts, Excerpta Medica / EMBASE, Google Scholar, CABI Full Text, Ulrich’s International Periodical Directory, ProQuest, Journalseek & Genamics, PhcogBase, EBSCOHost, Academic Search Complete, Open J-Gate, SciACCESS.
    Rapid publication: Average time from submission to first decision is 30 days and from acceptance to In Press online publication is 45 days.
    Open Access Journal: Phcog Commn. is an open access journal, which allows authors to fund their article to be open access from publication.

    © 2025 Pharmacognosy Communications. Maintained by Manuscript TechnoMedia LLP.

    Type above and press Enter to search. Press Esc to cancel.

    Scroll Up